Labcorp beats first-quarter estimates and raises full-year guidance
Updated
Updated · Barron's · Apr 30
Labcorp beats first-quarter estimates and raises full-year guidance
11 articles · Updated · Barron's · Apr 30
The diagnostics company reported adjusted earnings of $4.25 a share on $3.54bn in revenue, above forecasts of $4.12 and $3.51bn.
It now expects 2026 adjusted earnings of $17.70 to $18.35 a share and revenue growth of 5% to 6.1%, citing momentum in diagnostics and lab services.
Labcorp says AI, robotics and automation are improving operations as it expands complex testing, including cancer liquid biopsy and Alzheimer’s blood tests, though some investors still want stronger margin gains.
Labcorp's stock lags despite its AI push. Can its tech transformation overcome systemic industry pressures like reimbursement cuts and intense market competition?
As Labcorp launches advanced AI tools and tests, how will it ensure they are both clinically effective and financially accessible for everyday patient care?